Welcome to the BIOSTAT-CHF website. On our website we publish information regarding the BIOSTAT-CHF project, its progress and regularly we publish any news regarding the project.
Please read below the latest news, as well as a description of the project.
Dear investigators of BIOSTAT-CHF,
It is with great pleasure that we can announce that on December 18 in the afternoon, patient number 2500 of the BIOSTAT-CHF index study was enrolled!!
The first patient was recruited on December 20th, 2010. Over the past weeks, months and for almost 2 years you have all been so very important in this great success.
One practical remark; we realize that some of you may have already scheduled patients, so further patient recruitment can continue until tomorrow, Wednesday December 19th 2012, after which we will officially close our patient registration system.
The first part of our mission has now succeeded, and we thank all of you deeply, for all the efforts and help that you have given. The next steps will be focusing on data, samples and most importantly events. But we leave that for next year, for now please, just a big thank you for your efforts to date! Have a very Merry Christmas and a Happy New Year!
With best wishes,
Project manager BIOSTAT-CHF index study
Overall Top Recruiters - final status
1 - 157 patients - ITA - site 501 - Brescia - Prof.dr. M. Metra
1 - 157 patients - UK - site 801 - Hull - Prof.dr. J. Cleland
3 - 137 patients - NL - site 101 - Groningen - Prof.dr. D.J. van Veldhuisen
4 - 116 patients - NL - site 103 - Breda - Dr. Dunselman
5 - 104 patients - GRE - site 401 - Athens, Akkros - Prof.dr. F. Kolokatis
6 - 100 patients - SER - site 310 - Belgrade - Prof.dr. Radovanovic
7 - 95 patients - POL - site 701 - Wroclaw - Prof.dr. P. Ponikowski
8 - 91 patients - GER - site 301 - Berlin - Dr.med. H.D. Düngen
9 - 70 patients - SER - site 306 - Usice - Dr. Trifunovic
10 - 61 patients - NL - site 107 - Deventer - Dr. Lok
11 - 59 patients - POL - site 704 - Walbrzych - Dr. A. Jurczyk
12 - 57 patients - FRA - site 210 - Grenoble - Dr. Y. Neuder
13 - 54 patients - NOR - site 601 - Stavanger - Prof.dr. K. Dickstein
14 - 52 patients - SWE - site 602 - Linköping - Dr. U. Dahlström
15 - 51 patients - POL - site 703 - Piotkow Trybunalski - Dr. Ogorek
15 - 51 patients - SER - site 315 - Belgrade - Prof.dr. S. Dimkovic
Final Recruitment Push - Top recruiters since September 2012!
There is a final recruitment push since September. Below you can see the top 10 highest recruitment numbers since September:
1 - 35 patients - GRE - site 401 - Athens, Akkros - Prof.dr. F. Kolokatis
2 - 32 patients - NL - site 103 - Breda - Dr. Dunselman
3 - 29 patients - SER - site 310 - Belgrade - Prof.dr. Radovanovic
4 - 28 patients - POL - site 704 - Walbrzych - Dr. A. Jurczyk
4 - 28 patients - ITA - site 501 - Brescia - Prof.dr. M. Metra
6 - 27 patients - UK - site 801 - Hull - Prof.dr. J. Cleland
7 - 26 patients - SER - site 303 - Vrsac - Prof.dr. V. Petrovic
8 - 20 patients - SER - site 306 - Usice - Dr. Trifunovic
9 - 16 patients - NL - site 107 - Deventer - Dr. Lok
10- 15 patients - POL - site 701 - Wroclaw - Prof.dr. P. Ponikowski
10- 15 patients - SLO - site 311 - Golnik - Prof.dr. M. Lainscac
10- 15 patients - ITA - site 506 - Napoles - Dr. Limongelli
10- 15 patients - NL - site 101 - Groningen - Prof.dr. D.J. van Veldhuisen
2000th Patient included!
On September 11th, the 2000th BIOSTAT patient has been included by the team of site 401: Athens, Akkros of Dr. Fotis Kolokathis assisted by Dr. Giannis Alexanian. WELL DONE!
The Netherlands first to reach official target!
The BIOSTAT-CHF centers in the Netherlands have already reached their official target of 315 patients (18 June 2012). Even though we started two months later than anticipated, they still managed to include these patients four months ahead of schedule!
CONGRATULATIONS TO ALL CENTERS !!!
|Site 101 - Groningen - Prof.dr. D.J. van Veldhuisen - 115 patients|
Site 103 - Breda - Dr. Dunselman - 78 patients
Site 107 - Deventer - Drs. Lok - 41 patients
Site 102 - Goes - Drs. Roeters van Lennep - 28 patients
|Site 104 - Meppel - Drs. Hoogslag - 21 patients|
|Site 106 - Sneek - Dr. van Haelst - 20 patients|
|Site 105 - Almelo - Dr. G. Linssen - 12 patients|
PLEASE DON'T STOP!
Because there are other countries which are struggling, we do ask that all sites continue recruiting until we reach the 2500th patient.
In June 2012 a new recruitment record was set by the site of Prof.dr. S. Dimkovic. The BIOSTAT-CHF team at his site recruited 20 patients in the month June. This is an exceptional achievement!
1 - 20 patients - SER - Site 315 - Belgrade - Prof.dr. S. Dimkovic - jun-12
2 - 16 patients - ITA - Site 501 - Brescia - Prof.dr. M. Metra - sep-11
3 - 15 patients - UK - Site 801 - Hull - Prof.dr. J. Cleland - nov-11
3 - 15 patients - POL - Site 704 - Walbrzych - Dr. A. Jurczyk - oct-12
5 - 14 patients - SER - Site 310 - Belgrade - Prof. Radovanovic - mar - 12
5 - 14 patients - POL - Site 701 - Wroclaw - Prof.dr. P. Ponikowski - oct-12
7 - 13 patients - UK - Site 801 - Hull - Prof.dr. J. Cleland - jun-11
7 - 13 patients - NL - Site 103 - Breda - Dr. Dunselman - jul-11
7 - 13 patients - SER - Site 310 - Belgrade - Prof. Radovanovic - jan-12
7 - 13 patients - NL - Site 103 - Breda - Dr. Dunselman - oct-12
11 - 12 patients - SWE - Site 602 - Linköping - Ulf Dahlström - mrt-11
11 - 12 patients - ITA - Site 501 - Brescia - Prof.dr. M. Metra - jun-11
11 - 12 patients - POL - Site 704 - Walbrzych - Dr. A. Jurczyk - feb-12
11 - 12 patients - GRE - site 401 - Athens - Prof.dr. F. Kolokatis
1750 patients included!
On June 19th the 1750th BIOSTAT patient has been included by the team of site 702: Dr. Berkowski of the SP ZOZ Kłodzko, Poland. This site has impressed the BIOSTAT study management with a very steady recruitment rate over the past year, WELL DONE! As recruitment for the study as a whole is behind, we continue to need more and more patients so we hope they will continue to enroll as many patients as they can!
For the remaining 750 patients the countdown to zero has now begun!
1500 included, start of countdown
The 1500th patient was included in the index study. We have now started our countdown. Only 1000 more to go!
Brescia recruited 100th patient
On Tuesday the 14th of February, 2012, the study team in Brescia (Italy) were the first to recruit 100 patients in their BIOSTAT-CHF site. This is a very significant achievement.
The BIOSTAT-CHF Study Coordination Center would like to congratulate Prof.dr. Marco Metra and his entire study team with this achievement!
1000th patient in
2011 was a very succesful year. The recruitment target for that year was met and we nearly recruited a thousand patients in a single year.
As of January 5th 2012, the 1000th patient has been enrolled in Nancy, France.
All partners are thanked for their contribution!
First samples up for analysis!
The first samples were collected from different sites throughout Europe. In total samples were collected from 117 patients.
Part of these samples were already forwarded for analysis to the University of Leicester, to the team of Professor Ng.
100 patients in !
Already after a few months of recruitment, the 100th patient was enrolled.
First patient recruited!
In December 2010, in both The Netherlands (Groningen) and Norway (Stavanger) the first BIOSTAT-CHF patients were recruited! The study is now running!
Heart Failure is common in Europe and its prevalence is increasing as our population ages. Despite major improvements in care since the early 90s, it is still related to poor prognosis, an impaired quality of life and high health care costs. Many new therapies have failed to further improve outcome. One obvious reason is that the response to treatment is not homogenous. Treatment may need to be tailored to the individual patient. BIOSTAT-CHF aims to identify patients with a poor outcome, despite currently recommended therapy using information on demographics, gender, existing biomarkers, genetics and proteomics. Both genomic and proteomic analyses recently underwent major technical improvements, resulting in genome-wide analyses and detection of low abundance proteins. In BIOSTAT-CHF an index cohort of 2500 patients with worsening heart failure, will be recruited. Treatment will be optimized according to the heart failure guidelines of the European Society of Cardiology with diuretics, ACE-inhibitors, betablockers and aldosterone antagonists. When patients are optimally treated, any change in symptoms and exercise tolerance will be evaluated. Patients will then be followed up for a mean of 18 months, and mortality and heart failure hospitalizations will be recorded. By using a systems biology approach, incorporating information from demographic, biomarker, genomic, proteomic and the initial response to therapy, a risk prediction model will be designed, identifying patients with a poor outcome on currently recommended therapy. This model will then be validated in a real-life cohort of 2500 heart failure patients. BIOSTAT-CHF will therefore be a major step towards personalized medicine. Identifying patients with a poor outcome on currently recommended therapy might lead to further development of targeted therapies, eventually leading to improvements in outcome for patients with heart failure in Europe.
The BIOSTAT-CHF study has become possible due to the FP7 Health grant that the European Union has made available.